Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism-Reference-Cited by-同舟云学术

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism

Published:2015-08-04 Issue:2 Volume:30 Page:484-491
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Krupka C,Kufer P,Kischel R,Zugmaier G,Lichtenegger F S,Köhnke T,Vick B,Jeremias I,Metzeler K H,Altmann T,Schneider S,Fiegl M,Spiekermann K,Bauerle P A,Hiddemann W,Riethmüller G,Subklewe M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2015214.pdf

Reference39 articles.

1. Keir ME, Butte MJ, Freeman GJ, Sharpe AH . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677–704.

2. Chen L, Flies DB . Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13: 227–242.

3. Mellman I, Coukos G, Dranoff G . Cancer immunotherapy comes of age. Nature 2011; 480: 480–489.

4. Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252–264.

5. Postow MA, Callahan MK, Wolchok JD . Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015 2014; 59: 4358.

Cited by 206 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment;Frontiers in Pharmacology;2024-08-05

2. Bispecific antibodies: advancing precision oncology;Trends in Cancer;2024-08

3. Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies;Cancer Communications;2024-07-28

4. Facile Access to Branched Multispecific Proteins;Bioconjugate Chemistry;2024-06-16

5. Bispecific and multispecific antibodies in oncology: opportunities and challenges;Nature Reviews Clinical Oncology;2024-05-31